EDSA
Edesa Biotech, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Edesa Biotech, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Edesa Biotech, Inc.
2.32
+0.04 · +1.75%
No changes.
No changes.
No trades yet today.
No trades yet today.
| Manager | Value | % base | |
|---|---|---|---|
| Velan Capital | $6.7M | 22.04% | 0.00% |
| Rubric | $5.4M | 17.83% | −2.62% |
| Perceptive | $4.6M | 15.00% | 0.00% |
| Millennium | $4.6M | 14.96% | new |
| Stonepine | $3.7M | 12.16% | +1421.46% |
| Manager | Value | % base | |
|---|---|---|---|
| Velan Capital | $6.7M | 22.04% | 0.00% |
| Rubric | $5.4M | 17.83% | −2.62% |
| Perceptive | $4.6M | 15.00% | 0.00% |
| Millennium | $4.6M | 14.96% | new |
| Stonepine | $3.7M | 12.16% | +1421.46% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Edesa Biotech, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Edesa Biotech, Inc..
Annual filing, covered
10-K parsed · Dec 12 '25
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Dec 12 '25
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Expected move
No implied move.